Company logo

VIRI - Virios Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Alpharetta, United States
Type: Equity

VIRI price evolution
VIRI
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Current assets
Cash $7.7 $11.35 $14.01 $19.19
Short term investments
Net receivables
Inventory
Total current assets $9.04 $12.55 $15.78 $20.11
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $9.04 $12.55 $15.78 $20.11
Current liabilities
Accounts payable $0.67 $0.33 $0.35 $0.48
Deferred revenue
Short long term debt
Total current liabilities $1.9 $1.88 $1.28 $1.23
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $1.9 $1.88 $1.28 $1.23
Shareholders' equity
Retained earnings -$51.55 -$47.89 -$43.93 -$39.41
Other shareholder equity
Total shareholder equity $7.14 $10.67 $14.5 $18.88
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Current assets
Cash $14.01 $29.8 $0.31 $0.03
Short term investments
Net receivables
Inventory
Total current assets $15.78 $31.47 $0.32 $0.04
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $15.78 $31.47 $0.32 $0.07
Current liabilities
Accounts payable $0.35 $0.37 $0.04 $0.15
Deferred revenue
Short long term debt
Total current liabilities $1.28 $1.53 $1.62 $1.33
Long term debt $3.64
Total noncurrent liabilities $3.64
Total debt $3.64
Total liabilities $1.28 $1.53 $5.26 $1.33
Shareholders' equity
Retained earnings -$43.93 -$27.97 -$17.62 -$15.15
Other shareholder equity
Total shareholder equity $14.5 $29.94 -$5.02
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $2.41 $2.77 $2.92 $2.96
Selling, general & administrative $1.27 $1.19 $1.27 $1.15
Total operating expenses $3.67 $3.96 $4.19 $4.11
Operating income -$3.67 -$3.96 -$4.19 -$4.11
Income from continuing operations
EBIT -$3.67 -$3.96 -$4.51 -$4.11
Income tax expense
Interest expense -$0 -$0
Net income
Net income -$3.67 -$3.96 -$4.51 -$4.11
Income (for common shares) -$3.67 -$3.96 -$4.51 -$4.11
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $10.8 $0.19 $0.84
Selling, general & administrative $4.85 $9.81 $1.34
Total operating expenses $15.64 $10.01 $2.18 $1.96
Operating income -$15.64 -$10.01 -$2.18
Income from continuing operations
EBIT -$15.97 -$9.96 -$2.18
Income tax expense
Interest expense -$0.01 $0.38 $0.3 -$0.15
Net income
Net income -$15.96 -$10.35 -$2.47 -$2.11
Income (for common shares) -$15.96 -$10.35 -$2.47
(in millions $) 30 Jun 2022 31 Mar 2022 31 Dec 2021 30 Sep 2021
Net income -$3.67 -$3.96 -$4.51 -$4.11
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $0.14 $0.13 $0.13 $0.13
Total cash flows from operations -$3.66 -$2.66 -$5.18 -$2.65
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock -$0.3
Net borrowings
Total cash flows from financing
Effect of exchange rate
Change in cash and equivalents -$3.66 -$2.66 -$5.18 -$2.65
(in millions $) 31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Jan 2019
Net income -$15.96 -$10.35 -$2.47
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $0.32 $7.43
Total cash flows from operations -$15.69 -$3.9 -$2.09
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock -$0.1 $31.53
Net borrowings $1.93 $2.43
Total cash flows from financing -$0.1 $33.38 $2.37 $1.15
Effect of exchange rate
Change in cash and equivalents -$15.79 $29.49 $0.28 -$0.05
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue $0.00
EBITDA -$16.25M
EBIT -$16.25M
Net Income -$16.25M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA -113.09%
ROE -126.95%
Debt/Equity 0.09
Net debt/EBITDA 0.36
Current ratio 4.76
Quick ratio 4.76